Intratumoral heterogeneity and drug resistance in cancer

Table 3 Exosomal lncRNA/miRNA induced drug resistance in NSCLC

lncRNA/miRNA	Drug resistance	References
Circ-CPA4/let-7 miRNA	PD-L1/PD-1 antibody	Hong et al. [152]
miR-21	Cisplatin/gemcitabine/teniposide	Bica-Pop et al. [153]
miR-222-3p	Gemcitabine	Wei et al. [154]
miR-193a	Cisplatin	Wu et al. [155]
miR-130a		Zhang et al. [156]
miR-425-3p		Ma et al. [157]
miR-146a-5p		Yuden et al. [158]
miR-103a-3p		Wang et al. [159]
miR-4443		Song et al. [160]
miR-1273a		Zhao et al. [161]
circ_PIP5K1A/miR-101		Shao et al. [162]
circRNA_102481/miR-30a-5p	Gefitinib/erlotinib	Yang et al. [163]
lncRNA UFC1	PTEN inhibitor	Zang et al. [164]
lncRNA SOX2		Zhou et al. [165]
miR-214	Gefitinib	Zhang et al. [166]
lncRNA UCA1/miR143	Gefitinib	Chen et al. [167]
lncRNA RP11-838N2.4	Erlotinib	Zhang et al. [168]
lncRNA H19	Erlotinib	Pan et al. [169]
lncRNA MSTRG.292666.16	Osimertinib	Deng et al. [170]
miR-184 and miR-3913-5p		Li et al. [171]
miR-210		Hisakane et al. [172]
miR-136-5p	Anlotinib	Gu et al. [173]